GP1642



PATENT

Our Docket: P-LJ 5037

**X** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:

Reed et al.

Serial No.: 10/001,254

Filed: November 15, 2001

For: NOVEL DEATH DOMAIN PROTEINS

Examiner: Not Yet Known

Group Art Unit: 1642

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents,

Washington D.C., 20231 on

By: // leane K. W. of S. Melanile, K. Webster, Reg. No. 45,201

September 24, 2002 Date of Signature

Commissioner for Patents Washington, D.C. 20231

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97(d), enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449.

I hereby state under 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fees are deemed necessary in connection with the filing of this Information Disclosure Statement. However, if a

RECEIVED

OCT 0 2 2002

**TECH CENTER 1600/2900** 

Inventors:

Reed et al.

Serial No.:

10/001,254

Filed:

November 15, 2001

Page 2

fee is required, the Commissioner is hereby authorized to charge payment of this fee to Deposit Account No. 03-0370.

It is respectfully requested that these references be considered in the examination of this application and that their consideration be made of written record in the application file.

Respectfully submitted,

Melanie K. Webster

Registration No. 45,201 (858) 535-9001

Telephone: Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive 7<sup>th</sup> Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601

Commerce Patent and Trademark Office	Commonas Datant	ATTY DOCKET NO: P-LJ 5037	SERIAL NO. 10/001,254
	APPLICANT: Reed et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: November 15, 2001	GROUP: 1642

### U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
7						

#### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	WO 95/10630	04/20/95	PCT			,
	WO 98/39429	09/11/98	PCT			

# OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

Berger et al., "The apoptosis mediator mDAP-3 is a novel member of a conserved family of mitochondrial proteins," <u>Journal of Cell Science</u> , 113:3603-3612 (2000).
Feinstein et al., "The death domain: a module shared by proteins with diverse cellular functions," <u>Trends in Biochemical Sciences</u> , 20:342-344 (1995).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

RECEIVED

OCT 0 2 2002

PE		Page 2 of 2
Str 3 too End Trademark	ATTY DOCKET NO: P-LJ 5037	SERIAL NO. 10/001,254
	APPLICANT: Reed et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: November 15, 2001	GROUP: 1642

<b>.</b>	Han et al., "MRIT, a novel death-effector domain-containing protein, interacts with caspases and $BclX_L$ and initiates cell death," <u>Proc. Natl. Acad. Sci. USA</u> , 94:11333-11338 (1997).
٥	Hofmann, K., "The modular nature of apoptic signaling proteins," <u>Cell.</u> <u>Mol. Life Sci.</u> , 55:1113-1123 (1999).
	Kumar et al., "Identification of a Novel Tumor Necrosis Factor- $\alpha$ -inducible Gene, $SCC-S2$ , Containing the Consensus Sequence of a Death Effector Domain of Fas-associated Death Domain-like Interleukin-1 $\beta$ -converting Enzyme-inhibitory Protein," <u>J. Biol. Chem.</u> , 275:2973-2978 (2000).
	Liang and Fesik, "Three-dimensional Structures of Proteins Involved in Programmed Cell Death," <u>J. Mol. Biol.</u> , 274:291-302 (1997).
	Park et al., "Establishment of a High-Throughput Screening System for Caspase-3 Inhibitors," <u>Arch. Pharm. Res.</u> , 23:246-251 (2000).
	Reed and Tomaselli, "Drug discovery opportunities from apoptosis research," Current Opin. Biotech., 11:586-592 (2000).

RECEIVED

OCT 0 2 2002

	TECH CENTER 1600/290
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.